Funding
← Back to your selection

Janus Henderson Investors

Activity from announced rounds

Activity in this selectionSeries B

Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.

Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.

The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.

Sources
Rounds participated in
4
Confirmed lead rounds
0
2 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$415M
4 disclosed · full round size, not this investor’s share

By stage

Series B4

By primary sector

Biotech4

By country

United States3
United Kingdom1

Rounds

4 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Ambrosia Biosciences

Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.

$100MSeries B
Participant